TALK
Talkspace, Inc.
Medical - Care Facilities
Market Cap$869M
5Y Perf.-47.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TALK vs MNMD
Revenue, margins, valuation, and 5-year total return — side by side.
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.+294.8%
TALK vs MNMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TALK | MNMD |
|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology |
| Market Cap | $869M | $2.04B |
| Revenue (TTM) | $229M | $0.00 |
| Net Income (TTM) | $8M | $-184M |
| Gross Margin | 43.0% | — |
| Operating Margin | 1.4% | — |
| Forward P/E | 38.3x | — |
| Total Debt | $0.00 | $0.00 |
| Cash & Equiv. | $37M | $258M |
TALK vs MNMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TALK
MNMD
| Stock | Jul 20 | May 26 | Return |
|---|---|---|---|
| Talkspace, Inc. (TALK) | 100 | 53.0 | -47.0% |
| Mind Medicine (Mind… (MNMD) | 100 | 394.8 | +294.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TALK vs MNMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TALK leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Mind Medicine (MindMed) Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
TALK
Talkspace, Inc.
The Income Pick
TALK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.86
- Rev growth 22.0%, EPS growth 6.5%, 3Y rev CAGR 24.2%
- Lower volatility, beta 0.86, current ratio 6.38x
Best for: income & stability and growth exposure
MNMD
Mind Medicine (MindMed) Inc.
The Long-Run Compounder
MNMD is the clearest fit if your priority is long-term compounding.
- 5.1% 10Y total return vs TALK's -48.6%
- +227.9% vs TALK's +64.8%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TALK | 22.0% revenue growth vs MNMD's -64.9% |
| Stability / Safety | TALK | Beta 0.86 vs MNMD's 1.68 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MNMD | +227.9% vs TALK's +64.8% |
| Efficiency (ROA) | TALK | 5.9% ROA vs MNMD's -41.8%, ROIC 3.9% vs -389.5% |
TALK vs MNMD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTALKLAGGINGMNMD
MNMDMind Medicine (MindMe…
2leads
TALKTalkspace, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs MNMDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
MNMD2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TALK5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD5/6
Risk & VolatilityBeta, volatility, and downside exposure
TALK2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
TALK and MNMD operate at a comparable scale, with $229M and $0 in trailing revenue.
| Metric | TALKTalkspace, Inc. | MNMDMind Medicine (Mi… |
|---|---|---|
| RevenueTrailing 12 months | $229M | $0 |
| EBITDAEarnings before interest/tax | $7M | -$156M |
| Net IncomeAfter-tax profit | $8M | -$184M |
| Free Cash FlowCash after capex | -$2M | -$161M |
| Gross MarginGross profit ÷ Revenue | +43.0% | — |
| Operating MarginEBIT ÷ Revenue | +1.4% | — |
| Net MarginNet income ÷ Revenue | +3.4% | — |
| FCF MarginFCF ÷ Revenue | -0.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +29.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | -22.0% |
Insufficient data to determine a leader in this category.
Valuation Metrics
MNMD leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | TALKTalkspace, Inc. | MNMDMind Medicine (Mi… |
|---|---|---|
| Market CapShares × price | $869M | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $832M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | 129.75x | -10.04x |
| Forward P/EPrice ÷ next-FY EPS est. | 38.27x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 138.05x | — |
| Price / SalesMarket cap ÷ Revenue | 3.80x | — |
| Price / BookPrice ÷ Book value/share | 7.71x | 5.56x |
| Price / FCFMarket cap ÷ FCF | — | — |
MNMD leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
TALK leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
TALK delivers a 6.9% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-55 for MNMD. On the Piotroski fundamental quality scale (0–9), TALK scores 6/9 vs MNMD's 3/9, reflecting solid financial health.
| Metric | TALKTalkspace, Inc. | MNMDMind Medicine (Mi… |
|---|---|---|
| ROE (TTM)Return on equity | +6.9% | -55.3% |
| ROA (TTM)Return on assets | +5.9% | -41.8% |
| ROICReturn on invested capital | +3.9% | -3.9% |
| ROCEReturn on capital employed | +2.7% | -52.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 3 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$37M | -$258M |
| Cash & Equiv.Liquid assets | $37M | $258M |
| Total DebtShort + long-term debt | $0 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | -14.63x |
TALK leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TALK five years ago would be worth $5,237 today (with dividends reinvested), compared to $4,045 for MNMD. Over the past 12 months, MNMD leads with a +227.9% total return vs TALK's +64.8%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs TALK's 80.8% — a key indicator of consistent wealth creation.
| Metric | TALKTalkspace, Inc. | MNMDMind Medicine (Mi… |
|---|---|---|
| YTD ReturnYear-to-date | +47.9% | +51.7% |
| 1-Year ReturnPast 12 months | +64.8% | +227.9% |
| 3-Year ReturnCumulative with dividends | +491.1% | +510.3% |
| 5-Year ReturnCumulative with dividends | -47.6% | -59.6% |
| 10-Year ReturnCumulative with dividends | -48.6% | +512.1% |
| CAGR (3Y)Annualised 3-year return | +80.8% | +82.7% |
MNMD leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
TALK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TALK is the less volatile stock with a 0.86 beta — it tends to amplify market swings less than MNMD's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | TALKTalkspace, Inc. | MNMDMind Medicine (Mi… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.86x | 1.68x |
| 52-Week HighHighest price in past year | $5.20 | $21.09 |
| 52-Week LowLowest price in past year | $2.22 | $6.03 |
| % of 52W HighCurrent price vs 52-week peak | +99.8% | +98.1% |
| RSI (14)Momentum oscillator 0–100 | 66.2 | 64.9 |
| Avg Volume (50D)Average daily shares traded | 4.5M | 806K |
TALK leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TALK as "Hold" and MNMD as "Buy". Consensus price targets imply 1.2% upside for TALK (target: $5) vs -3.3% for MNMD (target: $20).
| Metric | TALKTalkspace, Inc. | MNMDMind Medicine (Mi… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $5.25 | $20.00 |
| # AnalystsCovering analysts | 10 | 1 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNMD leads in 2 of 6 categories (Valuation Metrics, Total Returns). TALK leads in 2 (Profitability & Efficiency, Risk & Volatility).
Best OverallTalkspace, Inc. (TALK)Leads 2 of 6 categories
Loading custom metrics...
TALK vs MNMD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TALK or MNMD a better buy right now?
Talkspace, Inc.
(TALK) offers the better valuation at 129. 8x trailing P/E (38. 3x forward), making it the more compelling value choice. Analysts rate Mind Medicine (MindMed) Inc. (MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TALK or MNMD?
Over the past 5 years, Talkspace, Inc.
(TALK) delivered a total return of -47. 6%, compared to -59. 6% for Mind Medicine (MindMed) Inc. (MNMD). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus TALK's -48. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TALK or MNMD?
By beta (market sensitivity over 5 years), Talkspace, Inc.
(TALK) is the lower-risk stock at 0. 86β versus Mind Medicine (MindMed) Inc. 's 1. 68β — meaning MNMD is approximately 96% more volatile than TALK relative to the S&P 500.
04Which has better profit margins — TALK or MNMD?
Talkspace, Inc.
(TALK) is the more profitable company, earning 3. 4% net margin versus 0. 0% for Mind Medicine (MindMed) Inc. — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TALK leads at 1. 4% versus 0. 0% for MNMD. At the gross margin level — before operating expenses — TALK leads at 43. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is TALK or MNMD more undervalued right now?
Analyst consensus price targets imply the most upside for TALK: 1.
2% to $5. 25.
06Which pays a better dividend — TALK or MNMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TALK or MNMD better for a retirement portfolio?
For long-horizon retirement investors, Talkspace, Inc.
(TALK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86)). Mind Medicine (MindMed) Inc. (MNMD) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TALK: -48. 6%, MNMD: +512. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TALK and MNMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TALK is a small-cap high-growth stock; MNMD is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.